Oncology Companion Diagnostics Xchange
Europe 2022
Munich, June 29
Welcome to hubXchange’s European Oncology Companion Diagnostics Xchange 2022, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing oncology companion diagnostics.
Discussion topics will cover Clinical Biomarkers, Clinical Development, Liquid Biopsies and Next-Generation CDx.
Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.
Please note this is an In-Person meeting with a hybrid option to join virtually.
Venue Details: Hilton Munich City, Rosenheimer Strasse 15, Munich
Clinical Biomarkers
Opening Keynote: Challenges in developing NGS based CDx; Sensitivity, Cost, serial testing for MRD and the increased use of liquid biopsies
- There is a clear shift to utilizing NGS based methods in favour of single analyte tests
- None the less, many countries have yet to adequately reimburse NGS based testing
- As minimally invasive tests utilizing liquid biopsy are developed, that enable multiple tests per patient throughout the treatment life-cycle, these costs will only increase
- To demonstrate adequate clinical utility, assays development must demonstrate robust sensitivity and specificity, as well as clinical utility
CEO, Predicine Europe
Dennis Merkle, PhD, MBA, is the Global Head of Biopharma Business and CEO of Predicine Europe. Dennis has over 20 years’ experience in Precision Oncology, having held numerous positions across both commercial and R&D functions in the pharmaceutical and diagnostics industries. Most recently he served as senior vice president of corporate development, oncology development strategy and alliance management at Invitae (formerly ArcherDx). Prior to that, Dennis was the global head of market enabling technologies and companion diagnostics at Merck KGaA, where he over-saw the development of numerous companion diagnostics across the entire Merck KGaA drug pipeline. Dennis was awarded an Alexander von Humboldt fellowship for his post-doctoral work at the Technical University of Dresden, Germany and obtained his BSc and PhD in Chemistry from the University of Calgary, Canada, focusing on DNA double-strand break repair mechanisms. Dennis also holds an MBA from Durham University Business School, UK.
Predictive biomarkers beyond PD-1/PD-L1 assays
- What have we learned from PD-L1?
- What’s next in the biomarker pipeline?
- New technologies – how do they help us already today?
- Is tissue the issue, then why don’t we go to blood?
Director, Clinical Biomarkers & Companion Diagnostics, Merck Group
Marcus Otte is Head of Biomarker Test Strategy & Profiling group in the Translational Medicine Department at Merck Healthcare KGaA. Before joining Merck Healthcare KGaA he worked at Definiens (Astra Zeneca), ORIDIS Biomarkers GmbH and Switch Biotech AG in several management and scientific positions in the drug and biomarker R&D field.
In his current role the focus is on translation and clinical implementation of new biomarker and assay technologies for patient selection and Mode-of-Action analysis in early and late clinical development.
Marcus received his PhD at the Technical University of Darmstadt (Germany) and did his Post-doc in Munich (Institute of Immunology) and Hamburg (University Hospital Eppendorf).
Validation of digital pathology workflows in a clinical setting
The current probability of success of a drug reaching the market from initial research is staggeringly low, only ~3%, how can workflows in digital pathology improve on these statistics? Will a multi-omics approach in clinical trials help?
Discussion of the practicalities and obstacles in implementing digital pathology workflows into a clinical setting, given the latest issues with the PDL1 assay, how can we improve discrepancies in available PD-L1 immunohistochemistry assays (https://dailynews.ascopubs.org/do/10.1200/ADN.22.200944/full/)
Discuss appropriate training and validation datasets
Associate Director, Scientific Affairs, Ultivue
Angela Vasaturo is Associate Director, Scientific Affairs at Ultivue. Prior to Ultivue, Angela was a Senior Researcher in Dr. Jerome Galon’s Laboratory of Integrative Cancer Immunology at the Cordeliers Research Center. From 2010-2015 Angela was a postdoctoral researcher in the field of Tumor Immunology at the NCMLS in Nijmegen, NL, and was the recipient of an EMBO short-term fellowship, amongst others. In 2012, Angela was among the first postdocs in Europe to be involved in the development of multiplex IHC and multispectral imaging and analysis of up to six
immunofluorescence markers, and today is considered a leading European expert in multiplex IHC
techniques, multispectral digital pathology, and tissue imaging.
1:25 – 2:25pm
Implementing evolving actionable biomarkers in clinical practice: opportunities and challenges
- Lack of evidence of prevalence of new biomarkers in the ”to be launched” country?
- How to ensure fast and effective implementations of new biomarker testing in clinical practice?
- Lack of reimbursement for biomarker-testings (how to deal with it)?
- Challenges pathologists facing as more and more biomarker testing are emerging?
- Comprehensive genomic profiling, way to go?
Oncology Diagnostics Liaison, AstraZeneca
Naresh Chandra, Ph.D., is trained as life-science researcher and now contributing to medical affairs with focus on Biomarkers in cancer care. Naresh has done his Ph.D. within virology and oncology from Umeå University, MIMS-EMBL, Sweden. After his Ph.D., Naresh has joined BioReperia, Linköping, Sweden, as International Representative Sales and Scientific Affairs. BioReperia has developed a novel in-vivo model for oncology drug discovery and is being evaluated as in vitro-diagnostics tool. Currently, he is working as Oncology Diagnostic Liaison, Sweden, at AstraZeneca. His main areas of interests and expertise are precision medicine /biomarker testing in cancer, liquid biopsy and digital pathology. His long term goal is to contribute in development and implementation of novel and reliable technologies for early cancer detection and screening.
3:45 – 4:45pm
The impact of the new EU IVD regulation on the pharmaceutical industry
- How will these new regulations impact patient access to precision medicines?
- How will the new EU regulatory changes for IVDs and CDx impact precision medicine development?
- How will these changes be implemented and who is going to pay for them?
- How will the UK will be aligned with Global and EU IVD and CDx Regulations?
Director, Precision Medicine Policy, AstraZeneca
Patrick is currently the Director of Precision Medicine Policy at AstraZeneca and is also a precision medicine representative at 2 industry trade bodies (EFPIA and ABPI) in their regulatory impact work streams. Patrick has worked in the pharmaceutical industry for the last 29 years, with 17 of these focused upon oncology precision medicines. In the last 4 years, his focus has been upon the changing European regulatory environment for companion diagnostics and IVDs and the impact upon precision medicine development. He holds a degree in Molecular Biology and a MBA, in addition to a post graduate certificate in health economics.
Clinical Development
Opening Keynote: Challenges in developing NGS based CDx; Sensitivity, Cost, serial testing for MRD and the increased use of liquid biopsies.
- There is a clear shift to utilizing NGS based methods in favor of single analyte tests
- None the less, many countries have yet to adequately reimburse NGS based testing
- As minimally invasive tests utilizing liquid biopsy are developed, that enable multiple tests per patient throughout the treatment life-cycle, these costs will only increase
- To demonstrate adequate clinical utility, assays development must demonstrate robust sensitivity and specificity, as well as clinical utility
CEO, Predicine Europe
Dennis Merkle, PhD, MBA, is the Global Head of Biopharma Business and CEO of Predicine Europe. Dennis has over 20 years’ experience in Precision Oncology, having held numerous positions across both commercial and R&D functions in the pharmaceutical and diagnostics industries. Most recently he served as senior vice president of corporate development, oncology development strategy and alliance management at Invitae (formerly ArcherDx). Prior to that, Dennis was the global head of market enabling technologies and companion diagnostics at Merck KGaA, where he over-saw the development of numerous companion diagnostics across the entire Merck KGaA drug pipeline. Dennis was awarded an Alexander von Humboldt fellowship for his post-doctoral work at the Technical University of Dresden, Germany and obtained his BSc and PhD in Chemistry from the University of Calgary, Canada, focusing on DNA double-strand break repair mechanisms. Dennis also holds an MBA from Durham University Business School, UK.
Designing impactful CDx strategies for early clinical development of new IO therapies
- What is the preferred biomarker for IO CDx? predictive? selective?
- Preclinical model selection – what impact it has on CDx
- Best strategies to translate into human setting
- Biomarker strategy for Ph 0-2: go broad or fail?
Global PHC Study Manager, Roche
Maria Karpova has a PhD in Human Geneticist. During her thesis and postdoc work, Maria had been working on the development of genomic approaches in translational medicine for various oncology indications, such as melanoma, spinalioma, basalioma and cutaneous T-cell lymphoma. In 2013 Maria started as biomarker research scientist at Roche in Münich. Now Maria is focusing on CDx product development as a Global Study Manager for Personalized Healthcare Solutions at Roche Diagnostics. Her current position is focused on delivering the necessary body of evidence in order to successfully register biomarker evaluation tests as companion diagnostics products across the world.
Designing CDx strategies for patient selection
- What are the challenges in validating clinical trial assays?
- LDTs can offer a low-cost pathway to accelerate the CDx co-development process.
- What are the challenges of choosing this approach, and how to overcome them?
- Bridging studies are critical for assay validation. What are the key considerations for successful bridging studies?
- How to successfully align the clinical validation strategy between drug developers and CDx developers?
Regulatory Affairs Project Manager, Servier
Ezgi Tulukcuoglu Guneri is a chemist by training and specialized in circulating tumor cell-based companion diagnostic assay development using microfluidics during her Ph.D. in Institut Curie in Paris. She joined The French Alternative Energies and Atomic Energy Commission as a post-doctoral researcher to study biomimetic materials. She then followed an advanced master’s in biotechnology & pharmaceutical management at Grenoble Ecole de Management, within which she completed her trainee program at Pfizer as a medical affairs manager. Currently, she serves as a project manager at Servier in the worldwide regulatory affairs department (pre-registration division) to deliver precision medicines treating rare cancers.
3:45 – 4:45pm
CDx approval and launch- from lab side to patients
- Challenges faced when implementing CDx assays in the labs vs patients
- CDx development and launch: financial/economic challenges
- CDx development and launch: regulatory challenges
- Strategies to implement personalised therapies for patients
Chief Executive Officer, and founder, Carcinotech
Ishani Malhotra, Chief Executive Officer, and founder of Carcinotech, has nine years’ experience in oncology and stem cell research with degrees from University of Edinburgh and a Certificate of Achievement from Harvard Medical School. She was listed as a Director of the Year Regional finalist at the Institute of Directors Scotland 2021 awards, has won several awards at national and international platforms and was recently recognised as one of 35 Rising Stars by Scottish Business Insider under 35. She has established significant international partnerships to advance Carcinotech’s vision of providing personalised drug testing platforms to help those suffering from cancer. Carcinotech manufactures 3D printed living tumours using patient biopsies to provide a platform for rapid, ethical, sustainable, and accurate drug screening, and personalised medicine testing.
Liquid Biopsies
Opening Keynote: Challenges in developing NGS based CDx; Sensitivity, Cost, serial testing for MRD and the increased use of liquid biopsies
- There is a clear shift to utilizing NGS based methods in favour of single analyte tests
- None the less, many countries have yet to adequately reimburse NGS based testing
- As minimally invasive tests utilizing liquid biopsy are developed, that enable multiple tests per patient throughout the treatment life-cycle, these costs will only increase
- To demonstrate adequate clinical utility, assays development must demonstrate robust sensitivity and specificity, as well as clinical utility
CEO, Predicine Europe
Dennis Merkle, PhD, MBA, is the Global Head of Biopharma Business and CEO of Predicine Europe. Dennis has over 20 years’ experience in Precision Oncology, having held numerous positions across both commercial and R&D functions in the pharmaceutical and diagnostics industries. Most recently he served as senior vice president of corporate development, oncology development strategy and alliance management at Invitae (formerly ArcherDx). Prior to that, Dennis was the global head of market enabling technologies and companion diagnostics at Merck KGaA, where he over-saw the development of numerous companion diagnostics across the entire Merck KGaA drug pipeline. Dennis was awarded an Alexander von Humboldt fellowship for his post-doctoral work at the Technical University of Dresden, Germany and obtained his BSc and PhD in Chemistry from the University of Calgary, Canada, focusing on DNA double-strand break repair mechanisms. Dennis also holds an MBA from Durham University Business School, UK.
Overcoming challenges of detecting low concentrations of ctDNA when identifying early to late stage tumours
|
CEO, Predicine Europe
Dennis Merkle, PhD, MBA, is the Global Head of Biopharma Business and CEO of Predicine Europe. Dennis has over 20 years’ experience in Precision Oncology, having held numerous positions across both commercial and R&D functions in the pharmaceutical and diagnostics industries. Most recently he served as senior vice president of corporate development, oncology development strategy and alliance management at Invitae (formerly ArcherDx). Prior to that, Dennis was the global head of market enabling technologies and companion diagnostics at Merck KGaA, where he over-saw the development of numerous companion diagnostics across the entire Merck KGaA drug pipeline. Dennis was awarded an Alexander von Humboldt fellowship for his post-doctoral work at the Technical University of Dresden, Germany and obtained his BSc and PhD in Chemistry from the University of Calgary, Canada, focusing on DNA double-strand break repair mechanisms. Dennis also holds an MBA from Durham University Business School, UK.
Beyond MRD: Developing Patient-Centered Diagnostics through Tumor-Informed Comprehensive Insights
- Earlier detection of disease recurrence
- Utility in more disease indications, and at earlier stages of disease
- Clinical trial needs for patient enrichment
- Screening/enrollment
- Surrogate endpoint analysis
- Necessity for additional biomarker readouts
PhD Executive Director, Europe Business Development, Personalis
With over 20 years of experience developing and commercializing new technologies to support the pharmaceutical, biotech and diagnostic industries, Dr. van der Lende currently leads the European Business Development Team at Personalis. Dr. van der Lende’s rich technical background spans all facets of drug-diagnostic co-development programs, with a focus on precision genomics and the adoption of novel biomarkers to improve oncology treatment decisions. Prior to joining Personalis Dr. van der Lende had various roles at QIAGEN, Premaitha and Definiens (AstraZeneca).
Considerations to overcome low CTC detection levels in early cancer patients
- What is the advantage using CTCs over other liquid Biopsy entities like ctDNA, Exosomes, miRNA etc.?
- How precisely can the therapy be defined using CTC-analyses at early stage and later stages?
- What is needed to get a reimbursement for CTC-analysis?
Founder and Managing Director, Telexos Deutschland
Erhard Fernholz PhD, Chemist, cofounder and CEO/Managing Director of Telexos, before >20 years at Roche Diagnostics as Portfolio/R&D team/project and innovation leader, developed more than 30 products, former leader of several governmental projects in Germany/EU, > 10 years experience in Liquid Biopsy.
Next-Generation CDx
Opening Keynote: Challenges in developing NGS based CDx; Sensitivity, Cost, serial testing for MRD and the increased use of liquid biopsies
- There is a clear shift to utilizing NGS based methods in favour of single analyte tests
- None the less, many countries have yet to adequately reimburse NGS based testing
- As minimally invasive tests utilizing liquid biopsy are developed, that enable multiple tests per patient throughout the treatment life-cycle, these costs will only increase
- To demonstrate adequate clinical utility, assays development must demonstrate robust sensitivity and specificity, as well as clinical utility
CEO, Predicine Europe
Dennis Merkle, PhD, MBA, is the Global Head of Biopharma Business and CEO of Predicine Europe. Dennis has over 20 years’ experience in Precision Oncology, having held numerous positions across both commercial and R&D functions in the pharmaceutical and diagnostics industries. Most recently he served as senior vice president of corporate development, oncology development strategy and alliance management at Invitae (formerly ArcherDx). Prior to that, Dennis was the global head of market enabling technologies and companion diagnostics at Merck KGaA, where he over-saw the development of numerous companion diagnostics across the entire Merck KGaA drug pipeline. Dennis was awarded an Alexander von Humboldt fellowship for his post-doctoral work at the Technical University of Dresden, Germany and obtained his BSc and PhD in Chemistry from the University of Calgary, Canada, focusing on DNA double-strand break repair mechanisms. Dennis also holds an MBA from Durham University Business School, UK.
3:45 – 4:45pm
Impact of Digital Pathology on development of novel Companion Diagnostics
- How can computational pathology and quantitative biomarker scoring impact development of CDx (e.g., robustness and performance, cut-off definition, scoring algorithms and scoring training purposes)?
- What bottlenecks needs to be resolved to speed-up adaptation of digital pathology workflows in clinical routine and translation to digital CDx solutions?
- Digital Pathology = Opportunity to generate more transparency, contribute to patient centric approach and open new markets?
Scientific Director, Merck
Thomas Mrowiec is an expert in Digital Pathology (DP) leading projects for tissue based biomarker development. He graduated from the University Heidelberg and specialized on digital image analysis to bridge biomarker strategies, histopathology and digital image quantification. His work has been applied in the field of immuno-oncology, e.g., digital scoring methods like the Immunoscore®. In his current role as Scientific Director and Lead Project Manager for DP at Merck Healthcare KGaA, Thomas is leading internal and external initiatives to implement DP as advanced tool for biomarker research and clinical development within the Precision Medicine strategy.